Measurement of Serum Antibodies to Selected Biologic Agents
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
This policy addresses testing for serum antibodies (and serum drug levels) to infliximab, adalimumab, vedolizumab, and ustekinumab in individuals treated for autoimmune inflammatory conditions and explains the payer's coverage stance.
No material clinical or coverage changes in this revision.
Coverage Criteria for Antidrug Antibody Testing
Not covered: Antidrug antibody testing
Policy statement indicates testing is not considered standard covered care.
Reactive testing in relapsed IBD — Covered when results will directly inform a management decision in relapsed patients
Covered when results will directly inform a management decision in relapsed patients:
Relapsed IBD patient criteria
- Specific actionable results: (1) Subtherapeutic drug level + undetectable ADA → consider dose escalation; (2) Subtherapeutic drug level + detectable ADA → consider switching to another TNF inhibitor; (3) Therapeutic drug level despite relapse → consider alternate drug class.
Derived from Roblin 2014, Afif 2010, and related cohorts
Required clinical context is supported by cited observational studies.
Proactive monitoring — Not supported for routine proactive monitoring
Not supported for routine proactive monitoring:
Based on Syversen et al. randomized trial and section summary concluding lack of convincing clinical utility for routine monitoring.
Overall clinical utility — Summary coverage stance based on evidence and guidelines
Summary coverage stance based on evidence and guidelines
References include Syversen et al. trial and multiple observational studies summarized in the policy.
Policy conclusion based on available direct evidence and guideline interpretations.
Guideline-recommended scenarios (IBD)
Guideline-based management scenarios
AGA guideline statements quoted and paraphrased from the policy's guideline summary.
The policy states that measurement of antidrug antibodies, alone or combined with serum biologic drug levels, is considered experimental / investigational and therefore is not standard covered care. Providers should refer to the member's contract benefits and any applicable state or federal mandates to determine coverage for an individual member.
This section does not list any explicit coverage exclusions beyond the policy findings summarized elsewhere; reviewers noted variability across studies but no discrete additional exclusion language is provided.
The evidence summary notes that routine or proactive ADA testing for all patients on biologic therapy is not supported by convincing evidence of clinical utility. An RCT and uncontrolled studies failed to demonstrate that scheduled therapeutic drug monitoring improves patient outcomes compared with standard care.
The review found no direct or indirect evidence of clinical utility for routine ADA testing in rheumatoid arthritis or spondyloarthritis; NICE concluded ELISA tests show promise but currently have insufficient evidence to recommend routine adoption in RA.
Based on available evidence and guideline assessments, testing for antidrug antibodies (with or without measurement of serum drug levels) is considered experimental/investigational for individuals receiving the specified biologic agents and is not established as standard covered care.
There are no standalone 'not medically necessary' declarations beyond the main policy determination; the document does not present additional explicit 'not medically necessary' phrasing in this section.
Randomized and controlled trials provide the strongest direct evidence. A large RCT (Syversen et al.) that used proactive therapeutic drug monitoring of infliximab (trough levels and ADA) found no difference in clinical remission at 30 weeks versus standard care. A smaller noninferiority trial in relapsed Crohn disease (Steenholdt et al.) showed algorithmic testing produced similar short-term response rates compared with dose intensification. Overall these trials do not demonstrate clear outcome benefit for routine proactive monitoring, limiting support for broad coverage.
The policy and summarized guideline guidance conclude that routine or indiscriminate ADA testing is not recommended. Testing may have a role when results will directly inform management in specific clinical scenarios (for example relapsed IBD), but routine periodic ADA measurement without clinical indication is not supported by current evidence.
Coding and Procedure Codes
| No codes listed |
Provider Actions, Prior Authorization, and Documentation
Prior Authorization and Benefit Verification
Measurement of antidrug antibodies (ADA) is considered experimental/investigational and is not routinely reimbursed under this policy. Prior authorization for ADA testing is not specified as a routine requirement in the policy; however, PA may be required by the member's contract or benefit plan. Verify member benefits and refer to the member's contract or BCBSKS Customer Service to determine if prior authorization is required for ADA testing.
- Prior authorization: None specified in this policy as a routine PA pathway; verify member benefits and refer to the member's contract or contact Blue Cross and Blue Shield of Kansas Customer Service.
- LDTs and commercial assays: Laboratory-developed tests must meet CLIA standards and reporting requirements.
Procedure Code Applicability and Coding Note
Procedure and billing codes listed in the policy are provided for informational purposes only. Inclusion of a code does not imply coverage or guarantee reimbursement. The codes below are applicable to testing described in the policy but are medically necessary only when the procedure is performed consistent with the Policy section.
None Specified / Not Addressed
This section does not specify additional provider actions beyond verification of benefits, documentation, and adherence to the Policy section. Some provider actions referenced elsewhere in the policy (for example, administrative or payer-specific prior authorization workflows) are not addressed here.
- Not addressed in this section: payer-specific PA workflows or step edits.
- Providers should consult the member's benefit plan and any separate utilization management requirements.
Assay Method and Timing Documentation
Document the assay type, assay method, and timing of specimen collection relative to the dosing schedule when ADA and drug levels are measured. Variation in assay methods (eg, ELISA, RIA, bridging assays) and timing of sample collection affects interpretation of results and clinical decision making.
- Record assay method (eg, ELISA, RIA, fluid-phase assays) and laboratory performing the test.
- Document timing of trough level relative to last dose (eg, pre-dose trough) and any concurrent immunosuppressive therapy that may affect immunogenicity.
Required Clinical Context and Medical Necessity Documentation
Clinical context must be documented for testing to be considered: objective evidence of relapse or loss of response, measurement of subtherapeutic drug trough levels, and other objective disease activity measures (eg, CDAI, Mayo score, calprotectin) when applicable. Medical necessity determinations are contingent on performance consistent with the Policy section.
- Required documentation: description of clinical relapse or loss of response, objective disease activity scores or biomarkers, and prior therapeutic interventions.
- Testing is medically necessary only when results would potentially impact management per the Policy (eg, in relapsed IBD after TNF inhibitor failure with subtherapeutic troughs).
Clinical Management Options, Algorithms, and Therapeutic Optimization Considerations
When managing loss of response to biologic therapy, consider evidence-based clinical management options and algorithms. For relapsed IBD after TNF inhibitor therapy, algorithmic approaches based on trough level and ADA presence have been proposed though they lack definitive RCT-proven outcome benefit.
- Clinical management options include: shortening dosing interval, increasing dose, switching to a different biologic within class, or switching to a different drug class/non-biologic.
- Algorithmic management steps (examples from literature and guidelines):
- - If trough concentration is sufficient: antibody testing should not guide treatment; consider non-drug causes of symptoms and alternative management.
- - If trough is low and antibodies are absent: optimize index drug (increase dose or shorten interval) and/or add immunomodulator.
- - If trough is zero and high‑titer antibodies are present: consider switching to a different agent within the class or to a different class.
- - If trough is zero and low‑titer antibodies are present: consider optimizing index drug (dose/interval/immunomodulator).
- Note: Proactive therapeutic drug monitoring did not show improved remission in an RCT; thus routine proactive TDM is not supported by current evidence.
Background and Scope
Biologic agents commonly discussed in this policy include infliximab, adalimumab, vedolizumab, and ustekinumab. Clinical practice experience and observational studies indicate that some patients are primary nonresponders (about 1 in 3) and that among initial responders a substantial proportion (≈20–60%) develop secondary loss of response. Antidrug antibodies (ADA) are one mechanism implicated in secondary nonresponse and have been associated with lower drug trough levels and increased risk of infusion- or injection-site reactions.
Definitions and Assay Descriptions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.